The South and Central America transcatheter heart valves market size is expected to reach US$ 235.5 million by 2033 from US$ 144.1 million in 2024. The market is estimated to record a CAGR of 5.7% from 2025 to 2033.
The South and Central America transcatheter heart valves market is gradually gaining traction, supported by demographic shifts, rising cardiovascular disease prevalence, and ongoing improvements in healthcare infrastructure. Countries across the region are recognizing the value of minimally invasive cardiac procedures, particularly as aging populations and lifestyle-related conditions such as obesity, hypertension, and diabetes contribute to higher incidences of valvular heart disease. Brazil has emerged as the dominant market, owing to its large patient base, expanding network of specialized hospitals, and government-backed initiatives to modernize healthcare delivery.
Momentum in this market is shaped by the growing availability of advanced cardiac centers, collaborations with international MedTech companies, and the rising awareness among patients regarding minimally invasive treatment options. Brazil's leadership is reinforced by its role as a hub for medical training and innovation, attracting expertise and technology transfer from global partners. However, challenges remain across the region. High procedural costs and limited reimbursement frameworks restrict accessibility, while disparities in healthcare access between urban and rural populations continue to pose barriers. Additionally, dependence on imported devices and the shortage of trained interventional cardiologists slow down widespread adoption.

Key segments that contributed to the derivation of the South and Central America transcatheter heart valves market analysis are valve type, application, and end user.
In South and Central America, valvular heart diseases continue to be a major cardiovascular health challenge. Rheumatic heart disease remains prevalent in many parts of the region, particularly affecting younger populations in rural and underserved areas. Urban centers are seeing an increase in age-related degenerative valve conditions, such as aortic stenosis and mitral regurgitation, due to rising life expectancy and lifestyle factors such as obesity and hypertension. As cardiac imaging and diagnostic access improve in cities, more patients are diagnosed at stages where intervention is necessary, highlighting the need for advanced treatment options.
Access to conventional open-heart surgery can be limited in many parts of South and Central America. Rural patients often face long travel distances to reach specialized cardiac centers, and surgical procedures can be costly or delayed due to hospital capacity constraints. Transcatheter heart valve therapies provide a minimally invasive alternative that reduces risk, recovery time, and hospital resource usage. This is particularly beneficial for older patients or those with comorbidities, helping hospitals expand care for patients who were previously considered high-risk or ineligible for surgery.
Governments and public-private initiatives are increasingly investing in cardiac care infrastructure, including catheterization labs and training for interventional cardiologists. Awareness campaigns and improved referral networks are also helping to identify patients earlier. These factors make the rising prevalence of valvular heart disease a key driver for the adoption of transcatheter heart valves across South and Central America.
Transcatheter interventions in South and Central America traditionally focused on aortic valves. However, there is an increasing attention on mitral and tricuspid valve disorders. Advanced imaging techniques and growing clinical expertise in urban cardiac centers are allowing physicians to diagnose these complex valve conditions more accurately. Hospitals in cities such as São Paulo, Buenos Aires, Mexico City, and Bogotá are expanding their procedural offerings, creating new opportunities for device manufacturers and healthcare providers.
Patients with mitral or tricuspid valve dysfunction are often older or have other health issues that make conventional surgery risky. Minimally invasive transcatheter therapies offer a safer alternative with faster recovery and reduced complication rates. Referral systems from smaller hospitals to urban cardiac centers are also increasing patient access to these procedures, boosting adoption and awareness throughout the region.
For medical device companies, this segment presents a significant growth opportunity. By providing training, procedural support, and educational programs, they can help local cardiologists build expertise in these interventions. As physician confidence and patient awareness increase, mitral and tricuspid valve therapies are poised to become a key growth segment in the South and Central American transcatheter heart valve market.
The South and Central America Transcatheter Heart Valves market demonstrates steady growth, with size and share analysis highlighting evolving trends and competitive dynamics among key players. The report further examines subsegments categorized within valve type, application, and end user, offering insights into their contribution to overall market performance.
By valve type, the aortic valve subsegment dominated the market in 2024. The aortic valve segment dominated due to the high prevalence of aortic stenosis, growing preference for minimally invasive transcatheter aortic valve replacement (TAVR), and technological advancements ensuring improved patient outcomes and procedural safety.
In terms of application, the aortic valve disease subsegment dominated the market in 2024. Aortic valve disease dominated the market as rising cases of calcific aortic stenosis and aging populations increased demand for transcatheter interventions, making it the most treated condition requiring advanced valve replacement solutions.
By end user, the hospitals subsegment dominated the market in 2024. Hospitals serve as primary centers for complex cardiovascular procedures, offering advanced infrastructure, skilled cardiologists, and comprehensive patient care, making them the leading setting for transcatheter heart valve adoption.
| Report Attribute | Details |
|---|---|
| Market size in 2024 | US$ 144.1 Million |
| Market Size by 2033 | US$ 235.5 Million |
| CAGR (2025 - 2033) | 5.7% |
| Historical Data | 2022-2023 |
| Forecast period | 2025-2033 |
| Segments Covered | By Valve Type
|
| Regions and Countries Covered | South and Central America
|
| Market leaders and key company profiles |
|
The "South and Central America Transcatheter Heart Valves Market Size and Forecast (2022–2033)" report provides a detailed analysis of the market covering below areas:
The geographical scope of the South and Central America Transcatheter Heart Valves market report is divided into: Brazil, Argentina, Chile, Colombia, Peru, and the Rest of South and Central America. Brazil held the largest share in 2024.
Brazil dominates the South and Central America transcatheter heart valves market due to its scale, infrastructure, and strategic healthcare investments. Major urban centers such as São Paulo, Rio de Janeiro, and Brasília have become focal points for advanced cardiac interventions, with leading hospitals increasingly performing transcatheter aortic valve replacement (TAVR) and related procedures. The country's leadership is reinforced by government-backed initiatives to expand tertiary care facilities, improve insurance coverage, and strengthen access to specialized cardiac services. Brazil's growing role in medical research and training enhances its position, as local physicians participate in international clinical trials and specialized programs.
Collaborations with global MedTech companies have accelerated the introduction of new valve technologies, while medical tourism adds another dimension to its dominance, attracting patients from neighboring countries seeking advanced treatments. Nonetheless, challenges persist. Rural populations often face limited access to specialized cardiac care, and the high cost of imported devices continues to be a barrier for broader adoption. Despite these limitations, Brazil remains the benchmark for transcatheter heart valve adoption in South and Central America, setting the standard for innovation, accessibility, and regional growth in minimally invasive cardiac interventions.
The South and Central America Transcatheter Heart Valves market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes crucial corporate publications, association data, and databases. A few of the key developments in the South and Central America Transcatheter Heart Valves market are:
The South and Central America Transcatheter Heart Valves Market is valued at US$ 144.1 Million in 2024, it is projected to reach US$ 235.5 Million by 2033.
As per our report South and Central America Transcatheter Heart Valves Market, the market size is valued at US$ 144.1 Million in 2024, projecting it to reach US$ 235.5 Million by 2033. This translates to a CAGR of approximately 5.7% during the forecast period.
The South and Central America Transcatheter Heart Valves Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South and Central America Transcatheter Heart Valves Market report:
The South and Central America Transcatheter Heart Valves Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South and Central America Transcatheter Heart Valves Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South and Central America Transcatheter Heart Valves Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)